1240967-48-9

Upstream product

• 1240970-58-4 ethyl 1-(6-(2-hydroxy-3-(trifluoromethyl)phenyl)pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate 
• 864359-18-2 tert-butyl 4-(4-(hydroxymethyl)phenyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

SGC ACTIVATORS FOR THE TREATMENT OF GLAUCOMA

An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a soluble guanylate cyclase (sGC) activator is disclosed. Also disclosed is a method of treating glaucoma an

Soluble Guanylate Cyclase Activators

This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.